Single Dose Study of MK-6194 in Healthy Japanese Participants

A Single Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-6194 in Healthy Japanese Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051210183

Enrollment

Registered

2022-03-02

Start date

2022-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

- Drug: MK-6194 MK-6194 1-7.5 mg subcutaneously administered in sterile solution form once - Drug: Placebo 5% glucose subcutaneously administered in sterile solution form once

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy Japanese male between the ages of 20 and 55 years with BMI within 18 to 25 kg/m2 inclusive and weight >=50 kg

Exclusion criteria

Exclusion criteria: History of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Secondary

Measure	Time frame
- AUC0-last, AUC0-inf, Cmax, Tmax, apparent t1/2, CL/F and Vz/F - Immunophenotyping of regulatory T cells	—

Contacts

Public Contactinquiry mailbox MSDJRCT

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026